LOS ANGELES, US/DUBAI, UAE: The UAE Ministry of Health and Prevention has authorised the use of Second Opinion, an artificial intelligence (AI) tool that assists in dental radiology. Produced by the company Pearl, the device is designed to help dental professionals scan and detect a wide range of dental conditions using radiographs.
Second Opinion applies computer vision technologies to detect a comprehensive array of pathologies, existing restorations and natural anatomy in dental radiographs. According to the company, the system analyses radiographs in real time, allowing dentists to display, review, add or reject the system’s detections while conducting examinations.
“With Second Opinion cleared, patients in the UAE can begin to gain the many benefits of AI-assisted dentistry and greater assurance in quality of care at Second Opinion-equipped dental practices,” said Dr Oussama Alaoui, head of prosthodontics at Harmony Medical Center in Abu Dhabi, in a press release. He added: “I look forward to witnessing the revolutionary impact and advantages that AI will bring to our dental care.”
Ophir Tanz, CEO and founder of Pearl, commented on the market launch: “Our Second Opinion technology enables more efficient and transparent doctor–patient communication while facilitating a higher standard of care. With the implementation of the platform in the UAE, we are excited to take a first step towards driving growth and better patient outcomes across Middle Eastern dentistry.”
In an interview, Tanz said that Second Opinion improves doctor–patient communication as dentists can clearly communicate their diagnosis with the support of the tool, giving their patients a greater sense of assurance. “It eliminates the doubt that makes patients seek a second opinion elsewhere—that is why we call it Second Opinion,” he explained.
The latest clearance follows the solution’s CE-marking in Europe, its Medical Device Establishment License for use in Canada, its clearance from the Therapeutic Goods Administration in Australia and, in New Zealand, its clearance from the New Zealand Medicines and Medical Devices Safety Authority.
More information on Second Opinion can be found at www.hellopearl.com/products/second-opinion.
Tags:
LOS ANGELES, US: Health regulators in New Zealand and Australia have provided market authorisation for Second Opinion, an artificial intelligence (AI) tool ...
BOSTON, US: Overjet, a dental start-up that develops software powered by artificial intelligence (AI), recently announced that it has received 510(k) ...
COLOGNE, Germany: Pearl, a leader in artificial intelligence (AI) systems for dental practices, announced today at IDS 2021 that its Second Opinion AI ...
WEST HOLLYWOOD, Calif., US: Second Opinion, an artificial intelligence (AI) diagnostic tool that assists in dental radiography, has been cleared by the US ...
ZURICH, Switzerland: Swiss-based start-up Odne has recently announced that it has received market clearance from the US Food and Drug Administration (FDA) ...
LOS ANGELES, US: Pearl, a global leader in dental artificial intelligence (AI) solutions, recently announced that it has raised US$58 million (€53.4 ...
LOS ANGELES, US: As 3D printing in dentistry evolves to become industry standard, the need for access to more materials is critical. In a step that ...
HONG KONG, China: Hong Kong has only 3.7 dentists per 10,000 residents, and its dental healthcare system is under pressure owing to an ageing population. ...
COLOGNE, Germany: As this year’s International Dental Show (IDS) unfolds, the COLTENE Group and its latest dental solutions remain at the forefront of ...
MIAMI, Fla., USA: Neocis, a supplier of robot-assisted dental implant surgery, has announced it has received 510(k) clearance from the U.S. Food and Drug ...
Live webinar
Mon. 23 June 2025
1:00 pm EST (New York)
Live webinar
Tue. 24 June 2025
2:00 pm EST (New York)
Live webinar
Tue. 24 June 2025
2:00 pm EST (New York)
Live webinar
Wed. 25 June 2025
11:00 am EST (New York)
Live webinar
Thu. 26 June 2025
12:00 pm EST (New York)
Live webinar
Fri. 27 June 2025
7:00 am EST (New York)
Dr. Panos Papaspyridakos, Dr. Armand Bedrossian
Live webinar
Fri. 27 June 2025
8:00 am EST (New York)
To post a reply please login or register